Vanda Pharmaceuticals
VNDA
150 hedge funds and large institutions have $225M invested in Vanda Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 51 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
8% more funds holding
Funds holding: 139 → 150 (+11)
6% more capital invested
Capital invested by funds: $212M → $225M (+$12.2M)
0.36% less ownership
Funds ownership: 76.34% → 75.97% (-0.36%)
2% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 51
54% less call options, than puts
Call options by funds: $812K | Put options by funds: $1.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFMC
Empire Financial Management Company
New York
|
+$2.61M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.47M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.3M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$830K |
| 5 |
KAM
Krensavage Asset Management
New York
|
+$720K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$3.95M |
| 2 |
BlackRock
New York
|
-$2.39M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$1.45M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.39M |
| 5 |
Morgan Stanley
New York
|
-$1.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Walleye Capital
New York
| – | -$445K | -94,298 | Closed |
|
152
Los Angeles Capital Management
Los Angeles,
California
| – | -$211K | -44,696 | Closed |
|
|
SG
153
StoneX Group
New York
| – | -$94.4K | -20,000 | Closed |
|
154
UBS AM
Chicago,
Illinois
| – | -$82.9K | -17,565 | Closed |
|
|
RS
155
R Squared
Central,
Hong Kong
| – | -$82.9K | -17,556 | Closed |
|
|
EC
156
EntryPoint Capital
New York
| – | -$82.7K | -17,520 | Closed |
|
|
VF
157
Virtu Financial
New York
| – | -$59K | -12,455 | Closed |
|
158
Wolverine Trading
Chicago,
Illinois
| – | -$54.6K | -11,417 | Closed |
|
|
CWM
159
CarsonAllaria Wealth Management
Glen Carbon,
Illinois
| – | -$755 | -160 | Closed |
|
160
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$722 | -153 | Closed |
|
|
HFS
161
Hughes Financial Services
Herndon,
Virginia
| – | -$511 | -121 | Closed |
|
|
C
162
Covestor
London,
United Kingdom
| – | +$171 | +37 | +128% |
|
VNDA Hedge Fund Activity: Q3 2025 in Review
150 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2025, worth a combined $225M — up 5.7% from $212M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VNDA positions and 13 closed out — a net gain of 11 holders — while 50 added to existing stakes and 51 trimmed.
The largest buyer was Empire Financial Management Company, adding an estimated $2.61M. The largest seller was Citigroup, cutting an estimated $3.95M.
- 150 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2025, up from 139 in Q2 2025.
- Funds reported $225M of Vanda Pharmaceuticals stock for Q3 2025, up 5.7% quarter-over-quarter.
- 24 funds opened new Vanda Pharmaceuticals positions in Q3 2025 and 13 closed out, a net change of +11 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2025 was Empire Financial Management Company, an estimated $2.61M added.
- The largest Vanda Pharmaceuticals seller in Q3 2025 was Citigroup, an estimated $3.95M sold.
Based on aggregated 13F filings for Q3 2025.